Asset Details
Do you wish to reserve the book?
Zongertinib in Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Zongertinib in Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer
Do you wish to request the book?
Zongertinib in Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Zongertinib in Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer
2025
Overview
Among patients with tumors harboring tyrosine kinase domain mutations who received zongertinib (a selective inhibitor of the HER2 tyrosine kinase), 71% had a response, and median progression-free survival was 12.4 months.
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Camptothecin - analogs & derivatives
/ Carcinoma, Non-Small-Cell Lung - drug therapy
/ Carcinoma, Non-Small-Cell Lung - genetics
/ Carcinoma, Non-Small-Cell Lung - mortality
/ Female
/ Humans
/ Immunoconjugates - therapeutic use
/ Lung Neoplasms - drug therapy
/ Male
/ Mutants
/ Mutation
/ Non-small cell lung carcinoma
/ Oncology
/ Receptor, ErbB-2 - antagonists & inhibitors
/ Trastuzumab - therapeutic use
/ Tumors
